Maxim Group Forecasts Lower Earnings for Nexalin Technology

Nexalin Technology, Inc. (NASDAQ:NXL) – Investment analysts at Maxim Group decreased their Q3 2026 EPS estimates for Nexalin Technology in a report issued on Monday, October 12th. Maxim Group analyst A. Vendetti now anticipates that the company will post earnings of ($2.91) per share for the quarter, down from their previous forecast of ($2.70). The consensus estimate for Nexalin Technology’s current full-year earnings is ($11.40) per share. Maxim Group also issued estimates for Nexalin Technology’s Q4 2026 earnings at ($2.34) EPS, FY2026 earnings at ($11.42) EPS and FY2027 earnings at ($7.55) EPS.

NXL has been the topic of a number of other research reports. Zacks Research raised Nexalin Technology to a “hold” rating in a report on Thursday, October 1st. Weiss Ratings cut Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Nexalin Technology currently has a consensus rating of “Reduce”.

Nexalin Technology Stock Down 4.9%

Nexalin Technology stock opened at $2.51 on Thursday. Nexalin Technology has a one year low of $2.38 and a one year high of $50.70. The business’s fifty day moving average is $6.51 and its 200 day moving average is $10.21.

Nexalin Technology (NASDAQ:NXL) last announced its earnings results on Wednesday, August 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($3.00) by $2.89. Nexalin Technology had a negative net margin of 4,141.94% and a negative return on equity of 278.24%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.09 million.

Hedge Funds Weigh In On Nexalin Technology

An institutional investor recently bought a new position in Nexalin Technology stock. PEAK6 LLC bought a new stake in shares of Nexalin Technology, Inc. (NASDAQ:NXL) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 240,210 shares of the company’s stock, valued at approximately $79,000. PEAK6 LLC owned about 1.09% of Nexalin Technology as of its most recent filing with the Securities & Exchange Commission. 0.65% of the stock is currently owned by institutional investors and hedge funds.

About Nexalin Technology

Nexalin Technology, Inc is a medical device company focused on developing noninvasive neurostimulation technologies for mental health and neurological applications. Its products are designed to deliver cranial electrotherapy stimulation (CES), a form of electrical stimulation intended to influence brain activity without the use of pharmaceutical drugs or invasive procedures.

The company’s product portfolio includes the Gen-2 and Gen-3 Nexalin devices, which use proprietary waveform technology and electrodes placed on the head to administer treatment.